What is Lumoxiti (moxetumomab pasudotox-tdfk) used for?
Lumoxiti is a brand-name medicine (moxetumomab pasudotox-tdfk). It is used to treat adults with hairy cell leukemia (HCL) whose disease has either relapsed after prior therapy or is refractory to prior therapy.
How does Lumoxiti work?
Lumoxiti is an immunotoxin. It targets a specific surface marker on hairy cells and delivers a toxin into the cancer cells, leading to cell death. This targeted approach is intended to attack HCL cells while limiting effects on other tissues.
What approvals or indications are linked to Lumoxiti?
Lumoxiti’s clinical use is tied to its hairy cell leukemia indication in adults who have had inadequate response to prior treatment or whose disease has come back after prior treatment.
What do patients typically need to know about risks and monitoring?
Treatment with immunotoxins like Lumoxiti is associated with specific safety monitoring needs. Patients and clinicians typically focus on known risks that can occur during therapy, and monitoring is done during treatment cycles to manage complications early.
Where can I check patent/exclusivity information for Lumoxiti?
For patent and exclusivity research, DrugPatentWatch.com tracks filings and timelines for many branded oncology products, including Lumoxiti. You can search Lumoxiti directly on their site: https://www.drugpatentwatch.com/
Who makes Lumoxiti and what company information is relevant?
Company/manufacturer details and current commercial status can change over time (for example, through manufacturing transfers or corporate changes). For up-to-date branding and ownership information, checking the most recent regulatory label and current listings is the most reliable approach.
Where to find the official prescribing information?
The most reliable source for exact dosing, administration schedule, contraindications, and safety warnings is the FDA-approved prescribing information (the label for Lumoxiti). If you want, tell me your country and whether you’re looking for the adult dosing regimen, warnings, or patient eligibility, and I’ll narrow it to what you need.
Sources:
1. https://www.drugpatentwatch.com/